Wall Street analysts expect Ritter Pharmaceuticals Inc (NASDAQ:RTTR) to report earnings of ($0.37) per share for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Ritter Pharmaceuticals’ earnings. Ritter Pharmaceuticals reported earnings of ($0.83) per share in the same quarter last year, which suggests a positive year over year growth rate of 55.4%. The business is expected to issue its next quarterly earnings report on Friday, November 8th.
According to Zacks, analysts expect that Ritter Pharmaceuticals will report full-year earnings of ($1.30) per share for the current fiscal year. For the next financial year, analysts forecast that the firm will report earnings of ($0.55) per share. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Ritter Pharmaceuticals.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its earnings results on Wednesday, August 14th. The biotechnology company reported ($0.31) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.18.
Ritter Pharmaceuticals stock traded up $0.02 during midday trading on Friday, reaching $0.92. 59,663 shares of the stock traded hands, compared to its average volume of 407,384. The stock’s fifty day moving average is $1.00 and its 200-day moving average is $0.87. Ritter Pharmaceuticals has a 12 month low of $0.47 and a 12 month high of $2.56. The stock has a market cap of $8.65 million, a P/E ratio of -0.25 and a beta of 1.27.
An institutional investor recently bought a new position in Ritter Pharmaceuticals stock. Virtu Financial LLC acquired a new stake in Ritter Pharmaceuticals Inc (NASDAQ:RTTR) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 52,426 shares of the biotechnology company’s stock, valued at approximately $46,000. Virtu Financial LLC owned about 0.91% of Ritter Pharmaceuticals at the end of the most recent reporting period. 6.09% of the stock is currently owned by hedge funds and other institutional investors.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.
Further Reading: What is a Buy-Side Analyst?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.